The Alphabet, Celgene and Mayo Clinic-backed gut-body drug developer floated at the top of its range, after about $167m in VC funding.

The China-based liver disease treatment developer, whose backers include Tasly Pharmaceuticals, will float in Hong Kong following rule changes.

YY's live game streaming spinoff, which also counts Tencent as a major investor, is floating in the US at the top of its range.

The social commerce platform, backed by Tencent and Bertelsmann, has hired Morgan Stanley, Credit Suisse and China Renaissance as underwriters for its initial public offering.

The AMT, Accuron and Tianda Pharmaceuticals-backed cancer drug developer raised half of its initial target for the offering.

The Tokyo Electric and Chubu Electric-backed renewable energy provider is targeting an initial $386m, though share sales could take the offering to $1bn.

UCL spinout Autolus has filed for an initial public offering on Nasdaq and plans on using the proceeds to further develop its range of cancer treatments.

Mastercard, Intel, American Express and Santander could all exit the point-of-sale technology provider, which plans to float in Sweden.

The WuXi PharmaTech and Mayo Clinic-backed aging disease drug developer floated at the midpoint of its range.

The sleep apnea developer, backed by Medtronic and Johnson & Johnson, floated at the top of its range before seeing its stock rise 56% on the first day.